EPCA-2 in the early diagnosis of prostate cancer.
- Author:
De-Shui YU
1
;
Zhuo-Qun XU
Author Information
1. Department of Urology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, China. ydsxinyi@163.com
- Publication Type:Journal Article
- MeSH:
Antigens, Neoplasm;
analysis;
Early Diagnosis;
Humans;
Male;
Prostatic Neoplasms;
diagnosis
- From:
National Journal of Andrology
2010;16(6):552-555
- CountryChina
- Language:Chinese
-
Abstract:
More and more clinical evidence has confirmed the limitations of the use of serum PSA in the screening, detection and treatment of prostate cancer, and scientists are continuously seeking for new biomarkers of the disease. The discovery of early prostate cancer antigen 2 (EPCA-2) has provided a new base for the screening, detection, treatment and follow-up of prostate cancer.
